"The voice for cancer physicians and their patients in Massachusetts."

FDA APPROVALS

Complete List of FDA Oncology Approval Notifications

To see a complete list of FDA Oncology (Cancer) / Hematologic Malignancies Approval Notifications, visit the FDA's website.

FDA WEBSITE


Upcoming events

  • No upcoming events

MSCO CORPORATE MEMBER APPROVALS

<< First  < Prev   ...   10   11   12   13   14   Next >  Last >> 
  • 15 Jan 2019 2:45 PM | Anonymous

    The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

  • 14 Jan 2019 3:27 PM | Anonymous

    The U.S. Food and Drug Administration approved gilteritinib (Xospata; Astellas) for treatment of adult patients who have relapsed or refractory acut myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA approved test. Read full press release.

  • 14 Jan 2019 3:24 PM | Anonymous

    The U.S. Food and Drug Administration approved atezolizumab (Tecentriq; Genentech) in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. Read full press release.

  • 14 Jan 2019 3:08 PM | Anonymous

    The U.S. Food and Drug Administration approved romiplostim (Nplate; Amgen) for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Read full press release

  • 14 Jan 2019 3:02 PM | Anonymous

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Read full press release.

  • 14 Jan 2019 2:26 PM | Anonymous

    The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Read full press release.

  • 14 Jan 2019 2:02 PM | Anonymous

    The U.S. Food and Drug Administration approved ravulizumab-owvz (Ultomiris; Alexion Pharmaceuticals, Inc.) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Read full press release

<< First  < Prev   ...   10   11   12   13   14   Next >  Last >> 

Massachusetts Society of Clinical Oncologists ©2022

PO BOX 549154, Waltham, MA, 02454
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org


Powered by Wild Apricot Membership Software